Hopital Nord Franche Comte

Research site

France 100 Route De Moval, 90400 Trevenans, France

15 trials recruiting
Squamous cell carcinoma of head and neck · Pneumonia · Colorectal cancer metastatic
Adult patients

About Specializations

Hopital Nord Franche Comte in Trevenans, France specialises in clinical trials of conditions such as Squamous cell carcinoma of head and neck, Pneumonia, Colorectal cancer metastatic, Squamous cell carcinoma of the hypopharynx, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

100 Route De Moval90400 TrevenansFrance

Open in maps ↗

Recruiting now: 15 trials
Conditions studied: 25

More sites in Trevenans France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

36 clinical trials

Colorectal cancer stage III

Recruiting

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Registered drugNo placebo

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Unicancer

Contact Research Centre

Squamous cell carcinoma of the hypopharynx+1

Recruiting

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Centre Leon Berard

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Ivonescimab
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Acute respiratory failure

Recruiting

Study of High-Flow Nasal Oxygen During Intubation in Intensive Care Patients with Low Blood Oxygen Levels

Registered drugNo placebo

Study of High-Flow Nasal Oxygen During Intubation in Intensive Care Patients with Low Blood Oxygen Levels

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Oxygen
Sponsor:Centre Hospitalier Regional Universitaire De Tours

Contact Research Centre

Infection prophylaxis

Recruiting

Study on Preventing Infections in ICU Patients with Interferon Gamma and Sodium Chloride

Registered drug

Study on Preventing Infections in ICU Patients with Interferon Gamma and Sodium Chloride

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Centre Hospitalier Et Universitaire De Limoges

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study on Regorafenib with Cyclophosphamide, Capecitabine, and Aspirin for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Study on Regorafenib with Cyclophosphamide, Capecitabine, and Aspirin for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Anal squamous cell carcinoma

Recruiting

Study of Ezabenlimab and Drug Combination for Stage III Anal Cancer Treatment

Registered drugNo placebo

Study of Ezabenlimab and Drug Combination for Stage III Anal Cancer Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Gastrooesophageal cancer+1

Recruiting

Study on the Safety of Trifluridine/Tipiracil for Patients with Dihydropyrimidine Dehydrogenase Deficiency and Metastatic Colorectal or Gastroesophageal Cancer

Registered drugNo placebo

Study on the Safety of Trifluridine/Tipiracil for Patients with Dihydropyrimidine Dehydrogenase Deficiency and Metastatic Colorectal or Gastroesophageal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Unicancer

Contact Research Centre

Colon cancer

Recruiting

Study on Using Oxaliplatin, Fluorouracil, and Folinic Acid for Treating Stage II Colon Cancer in Patients with Positive Circulating Tumor DNA

Registered drugNo placebo

Study on Using Oxaliplatin, Fluorouracil, and Folinic Acid for Treating Stage II Colon Cancer in Patients with Positive Circulating Tumor DNA

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study on Regorafenib with Capecitabine, Cyclophosphamide, and Aspirin for Patients with Metastatic Colorectal Cancer Resistant to Chemotherapy

Registered drugNo placebo

Study on Regorafenib with Capecitabine, Cyclophosphamide, and Aspirin for Patients with Metastatic Colorectal Cancer Resistant to Chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Rheumatoid arthritis

Recruiting

Study on Baricitinib and Anti-TNF Drug Combination for Patients with Rheumatoid Arthritis

Registered drug

Study on Baricitinib and Anti-TNF Drug Combination for Patients with Rheumatoid Arthritis

Registered drug

France

Participants:18–64 years
Substances:Adalimumab
Sponsor:Centre Hospitalier Universitaire De Bordeaux

Contact Research Centre

Autoimmune haemolytic anaemia

Recruiting

Study on the Effectiveness of Apixaban and Enoxaparin Sodium in Preventing Blood Clots in Patients with Autoimmune Hemolytic Anemia

Registered drugNo placebo

Study on the Effectiveness of Apixaban and Enoxaparin Sodium in Preventing Blood Clots in Patients with Autoimmune Hemolytic Anemia

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites